SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Medical Quality
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1062860609332509v1
24/3/241    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Eddy, D. M.
Right arrow Articles by Schaaf, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eddy, D. M.
Right arrow Articles by Schaaf, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Effect of Smoking Cessation Advice on Cardiovascular Disease

David M. Eddy, MD, PhD

Archimedes, Inc, San Francisco, California, author{at}archimedesmodel.com

Barbara Peskin, PhD

Archimedes, Inc, San Francisco, California

Andrei Shcheprov, PhD

Archimedes, Inc, San Francisco, California

Greg Pawlson, MD, MPH

NCQA, Washington, DC

Sarah Shih, MPH

NCQA, Washington, DC

David Schaaf, MD

Pfizer Inc, New York, NY

Performance measures and guidelines encourage physicians to advise smokers to quit. The effect of these efforts on the morbidity, mortality, and cost of cardiovascular disease is not known. This article analyzes the effects of offering smoking cessation advice in the US population. The Archimedes model is used to simulate several clinical trials in which basic advice and medication advice are offered and to calculate the rates of myocardial infarctions, congestive heart disease deaths, strokes, life years, quality-adjusted life years (QALYs), costs, and cost/ QALY. The simulated population is a representative sample of the US population drawn from the Third National Health and Nutrition Survey conducted just before the performance measures and guidelines were introduced. The results show that offering basic advice and medication advice can prevent about 13% and 19% of myocardial infarctions and strokes, respectively. The 30-year cost/QALY is approximately $3000 less than the base-case assumptions and less than $10 000 under pessimistic assumptions.

Key Words: smoking cessation • cardiovascular disease • outcome study • performance measures

This version was published on May 1, 2009

American Journal of Medical Quality, Vol. 24, No. 3, 241-249 (2009)
DOI: 10.1177/1062860609332509
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement